Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma, T-Cell 2Pancreatic Neoplasms 1Oligodendroglioma 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Inflammatory Breast Neoplasms 1Gliosarcoma 1Glioblastoma 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 18Trastuzumab 16Paclitaxel 15Taxes 11Doxorubicin 11Radiotherapy 7Lapatinib 6Albumin-Bound Paclitaxel 6Vorinostat 5Tamoxifen 5Docetaxel 5Carboplatin 5Capecitabine 5Bevacizumab 5Radiation 4Letrozole 4Immunohistochemistry 4Anastrozole 4sargramostim 3pegfilgrastim 3exemestane 3Magnetic Resonance Spectroscopy 3Immunoenzyme Techniques 3Granulocyte-Macrophage Colony-Stimulating Factor 3Granulocyte Colony-Stimulating Factor 3Fluorodeoxyglucose F18 3Flow Cytometry 3Filgrastim 3Chemotherapy, Adjuvant 3saponin QA-21V1 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Breast Neoplasms, Male × Depsipeptides × Clear all
NCT01938833 2025-05-16

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Thomas Jefferson University

Phase 1/2 Terminated
9 enrolled 7 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡